Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Unique Inflammatory Signature in Hemophilic Arthropathy: Epigenetic Changes Due to Interaction between Blood and Fibroblast-like Synoviocytes

Sandra Mignot, Chantal Rothschild, MD, Annie Harroche, MD, Julien Even, MD, Nicolas Cagnard, PhD, Richard Delarue, MD, Benoit Albaut, PhD, Olivier Hermine, MD PhD, Laurent Frenzel, MD PhD

Blood (2017) 130 (Supplement 1): 3669.

https://doi.org/10.1182/blood.V130.Suppl_1.3669.3669

Published: 2017

Journal Articles

Use of Power Doppler Ultrasound in Haemophilia Could Predict Early Relapse of Intra Articular Bleeding after Haemarthrosis: A Prospective Cohort of 27 Haemarthrosis Monitored By Articular Ultrasound

Laurent Frenzel, MD PhD, Stephanie Luzy, MD, Cecile Lozach, MD, Richard Delarue, MD, Olivier Hermine, Annie Harroche, MD, Chantal Rothschild, MD, Sylvain Breton, MD

Blood (2015) 126 (23): 1086.

https://doi.org/10.1182/blood.V126.23.1086.1086

Published: 2015

Journal Articles

Response: Confounding by indication is unlikely to explain the higher inhibitor incidence in boys treated with a recombinant FVIII product

Thierry Calvez, Hervé Chambost, Patrick Lutz, Chantal Rothschild, Jenny Goudemand

Blood (2015) 125 (24): 3817–3819.

https://doi.org/10.1182/blood-2015-02-622167

Published: 2015

Includes: Supplemental data

Journal Articles

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A

Thierry Calvez, Hervé Chambost, Ségolène Claeyssens-Donadel, Roseline d’Oiron, Véronique Goulet, Benoît Guillet, Virginie Héritier, Vanessa Milien, Chantal Rothschild, Valérie Roussel-Robert, Christine Vinciguerra, Jenny Goudemand

Blood (2014) 124 (23): 3398–3408.

https://doi.org/10.1182/blood-2014-07-586347

Published: 2014

Includes: Supplemental data

Journal Articles

Treatment of Von Willebrand Disease Women Undergoing Childbirth with a Von Willebrand Factor Product with a Low Content of Factor VIII: Results From 4 Multicenter Studies

Catherine Boyer-Neumann, Annie Borel-Derlon, MD, PhD, Jenny Goudemand, MD, PhD, Ségolène Claeyssens, Pierre-Marie Sie, MD, PhD, Philippe Moreau, Marie-Anne Bertrand, MD, Chantal Rothschild, MD, Benoît Guillet, MD, PhD, Jeanne Yvonne Borg, Catherine Chatelanaz, Wil Stevens, Françoise Bridey, Celine Henriet

Blood (2012) 120 (21): 3375.

https://doi.org/10.1182/blood.V120.21.3375.3375

Published: 2012

Journal Articles

Development of Inhibitory Antibodies to Therapeutic Factor VIII in Severe Hemophilia A Is Associated with Microsatellite Polymorphism in the HMOX1 promoter

Yohann Repesse, PhD, Ivan Peyron, Jordan Dimitrov, PhD, Suryasarathi Dasgupta, PhD, Elika Farrokhi Moshai, Annie Borel-Derlon, MD, PhD, Catherine Costa, MD, Benoist Guillet, MD, PhD, Roseline d'Oiron, MD, Achille Aouba, MD, Chantal Rothschild, MD, Johannes Oldenburg, MD, Ana Pavlova, MD, Srinivas Kaveri, D. V. M., Ph.D, Sebastien Lacroix-Desmazes, PhD

Blood (2012) 120 (21): 38.

https://doi.org/10.1182/blood.V120.21.38.38

Published: 2012

Journal Articles

FVIII Specific Memory B Lymphocytes in Hemophilia A with Inhibitors Treated by Immune Tolerance Induction.

Isabelle Diaz, Karine Bollore, Chantal Rothschild, Hervé Chambost, Ségolène Claeyssens, Edouard Tuaillon, Priscilla Lapalud, Jean-François Schved, Jean-Pierre Vendrell, Géraldine Lavigne-Lissalde

Blood (2009) 114 (22): 3162.

https://doi.org/10.1182/blood.V114.22.3162.3162

Published: 2009

Journal Articles

Absence of collagen-induced platelet activation caused by compound heterozygous GPVI mutations

Bénédicte Dumont, Dominique Lasne, Chantal Rothschild, Maxime Bouabdelli, Véronique Ollivier, Claire Oudin, Nadine Ajzenberg, Bernard Grandchamp, Martine Jandrot-Perrus

Blood (2009) 114 (9): 1900–1903.

https://doi.org/10.1182/blood-2009-03-213504

Published: 2009

Includes: Supplemental data

Journal Articles

Dramatic Efficacy of Sequential Bypassing Agent Treatment for a Life-Threatening Bleeding in An Infant with Severe Hemophilia and Inhibitor

Chantal Rothschild, Laurent Dupic, Annie Harroche, Marie-Francoise Torchet, Achille Aouba, Veronique Abadie, Christelle Chalouhi

Blood (2008) 112 (11): 4501.

https://doi.org/10.1182/blood.V112.11.4501.4501

Published: 2008

Journal Articles

Absent Collagen-Induced Platelet Activation in a Patient Double Heterozygous for Two GPVI Mutations

Martine Jandrot-Perrus, Bénédicte Dumont, Dominique Lasne, Chantal Rothschild, Bernard Grandchamp, Nadine Ajzenberg

Blood (2008) 112 (11): 88.

https://doi.org/10.1182/blood.V112.11.88.88

Published: 2008

Journal Articles

French Multicenter Study for Post-Marketing Survey of WILFACTIN®: A Von Willebrand Factor Concentrate with a Low FVIII Content.

Annie Borel-Derlon, Jenny Goudemand, Chantal Rothschild, Catherine Chatelanaz, Françoise Bridey, French Post-Marketing Study Group5

Blood (2006) 108 (11): 4052.

https://doi.org/10.1182/blood.V108.11.4052.4052

Published: 2006

Journal Articles

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A

Jenny Goudemand, Chantal Rothschild, Virginie Demiguel, Christine Vinciguerrat, Thierry Lambert, Hervé Chambost, Annie Borel-Derlon, Ségolène Claeyssens, Yves Laurian, Thierry Calvez, the members of the FVIII-LFB and Recombinant FVIII study groups

Blood (2006) 107 (1): 46–51.

https://doi.org/10.1182/blood-2005-04-1371

Published: 2006

Journal Articles

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B

Amy D. Shapiro, Jorge Di Paola, Alice Cohen, K. John Pasi, Margaret A. Heisel, Victor S. Blanchette, Thomas C. Abshire, W. Keith Hoots, Jeanne M. Lusher, Claude Negrier, Chantal Rothschild, David A. Roth, for the Recombinant Factor IX Study Group

Blood (2005) 105 (2): 518–525.

https://doi.org/10.1182/blood-2004-06-2283

Published: 2005

Journal Articles

Mild / Moderate Hemophilia A with Factor VIII Inhibitors (MHAI): Results of a French and Belgian Survey.

Roseline d’Oiron, Jean Maurice Lavergne, Jenny Goudemand, Annie Borel-Derlon, Claude Guerois, Chantal Rothschild, Kathelijne Peerlinck, Herve Chambost, Natalie Stieltjes, the Belgian French MHAI Study Group

Blood (2004) 104 (11): 3088.

https://doi.org/10.1182/blood.V104.11.3088.3088

Published: 2004

Journal Articles

Immune Tolerance with a High Purity Plasma Derived Factor VIII Containing Von Willebrand Factor in Haemophilia A Patients with High Responding Inhibitors.

Benoit Polack, MD, PhD, Philippe Beurrier, MD, Chantal Rothschild, MD, Frédérique Orsini, Albert Faradji, MD, Anne Liennhard, MD, Edith Fressinaud, MD, PhD, Jenny Goudemand, MD

Blood (2004) 104 (11): 3096.

https://doi.org/10.1182/blood.V104.11.3096.3096

Published: 2004

NARROW

Unique Inflammatory Signature in Hemophilic Arthropathy: Epigenetic Changes Due to Interaction between Blood and Fibroblast-like Synoviocytes

Use of Power Doppler Ultrasound in Haemophilia Could Predict Early Relapse of Intra Articular Bleeding after Haemarthrosis: A Prospective Cohort of 27 Haemarthrosis Monitored By Articular Ultrasound

Response: Confounding by indication is unlikely to explain the higher inhibitor incidence in boys treated with a recombinant FVIII product

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A

Treatment of Von Willebrand Disease Women Undergoing Childbirth with a Von Willebrand Factor Product with a Low Content of Factor VIII: Results From 4 Multicenter Studies

Development of Inhibitory Antibodies to Therapeutic Factor VIII in Severe Hemophilia A Is Associated with Microsatellite Polymorphism in the HMOX1 promoter

FVIII Specific Memory B Lymphocytes in Hemophilia A with Inhibitors Treated by Immune Tolerance Induction.

Absence of collagen-induced platelet activation caused by compound heterozygous GPVI mutations

Dramatic Efficacy of Sequential Bypassing Agent Treatment for a Life-Threatening Bleeding in An Infant with Severe Hemophilia and Inhibitor

Absent Collagen-Induced Platelet Activation in a Patient Double Heterozygous for Two GPVI Mutations

French Multicenter Study for Post-Marketing Survey of WILFACTIN®: A Von Willebrand Factor Concentrate with a Low FVIII Content.

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B

Mild / Moderate Hemophilia A with Factor VIII Inhibitors (MHAI): Results of a French and Belgian Survey.

Immune Tolerance with a High Purity Plasma Derived Factor VIII Containing Von Willebrand Factor in Haemophilia A Patients with High Responding Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only